Adaptimmune Therapeutics plc Cash Flow-to-Debt Ratio
Adaptimmune Therapeutics plc cash flow-to-debt ratio. Adaptimmune Therapeutics plc (473A) has a Cash Flow-to-Debt Ratio of -0.17x as of June 2025, meaning its operating cash flow of €-34.78 Million could theoretically repay 0% of its total liabilities (€201.59 Million) in one year. Check cash flow quality index of Adaptimmune Therapeutics plc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Adaptimmune Therapeutics plc (2016–2024)
Cash flow-to-debt ratio of Adaptimmune Therapeutics plc from 2016 to 2024. Historical debt coverage capacity for Adaptimmune Therapeutics plc across 9 annual periods. Check total reinvestment intensity of Adaptimmune Therapeutics plc to assess the company's total reinvestment commitment from operating cash flow.
Adaptimmune Therapeutics plc Cash Flow-to-Debt Ratio by Year (2016–2024)
Adaptimmune Therapeutics plc cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Adaptimmune Therapeutics plc. For the full cash flow conversion analysis, see 473A operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | €-73.21 Million | €234.11 Million | ▲ +46.0% |
| 2023 | -0.58x | €-140.88 Million | €243.10 Million | ▼ -1.0% |
| 2022 | -0.57x | €-141.77 Million | €247.04 Million | ▼ -1509.9% |
| 2021 | 0.04x | €10.73 Million | €263.58 Million | ▲ +108.3% |
| 2020 | -0.49x | €-53.59 Million | €109.92 Million | ▲ +74.9% |
| 2019 | -1.94x | €-112.51 Million | €57.91 Million | ▲ +44.4% |
| 2018 | -3.50x | €-104.39 Million | €29.85 Million | ▼ -403.2% |
| 2017 | -0.69x | €-54.31 Million | €78.16 Million | ▲ +1.4% |
| 2016 | -0.70x | €-48.17 Million | €68.37 Million | — |